Armata Pharmaceuticals, Inc.
ARMP · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | -0.01 | 0.01 | -0.04 |
| FCF Yield | -4.21% | -10.70% | -14.54% | -11.73% |
| EV / EBITDA | 0.00 | -14.43 | -68.89 | 29.42 |
| Quality | ||||
| ROIC | 0.00% | -14.09% | -9.76% | -12.92% |
| Gross Margin | 0.00% | 83.13% | 23.22% | 69.23% |
| Cash Conversion Ratio | 0.16 | 0.44 | 1.16 | -3.05 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.64% | 18.14% | -2.49% | -2.06% |
| Free Cash Flow Growth | 38.32% | 4.15% | 2.18% | 14.70% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -8.76 | -48.19 | 18.73 |
| Interest Coverage | 0.00 | -1.80 | -2.27 | -3.21 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -147.34 | -190.57 | -127.20 |